AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 51 min read$RCEL

Woody Joseph Fralin purchased $41K of RCEL

Woody Joseph Fralin purchased 10,000 shares of AVITA Medical, Inc. (RCEL) at an average of $4.09 ($4.09–$4.10) across 2 trades on 2026-06-03.

Original reporting
SEC EDGAR · Woody Joseph Fralin
Published Jun 5, 2026, 9:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 3:58 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$RCEL
Neutral
medium confidence
Mentioned
$RCEL
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RCELNeutralLow
01

Why it matters

The director's purchase modestly raises confidence but unlikely to move the stock significantly.

02

Market read

Small insider buy; limited immediate trading relevance.

03

What to watch

Potential upcoming corporate actions or financing needs not disclosed.

Relevance 4/10Novelty 4/10Timing: filing today

Background

Form 4 filing reports insider transactions; provides primary source data.

Company-level read

Ticker impact

$RCELNeutralMedium confidence
Context

Director Woody Joseph Fralin bought 10,000 shares of Avita Medical (RCEL) for $40,949, increasing his stake to 92,761 shares.

Expected impact

likely slight upward pressure as market digests insider buying.

Evidence & confidence

Purchase amount under $50k and director role suggest limited market impact; price may edge higher on positive sentiment.

Market effects

Sector

Minimal effect on medical device sector; insider activity is routine.

Regional

No regional impact.

Global

Not globally relevant.

Counterpoint

What could challenge this read

Insider purchase could be a routine portfolio adjustment, not a bullish signal.

Key entities

  • Company
    Avita Medical, Inc.

    Medical device company listed on NASDAQ under RCEL.

  • Individual
    Woody Joseph Fralin

    Director of Avita Medical.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

RCEL insider trading history →

Related articles

AUG 18
$RCELMedAI 8/10

Avita Medical Raises 2026 Revenue Outlook as Q2 Sales Climb 18%

Avita Medical (NASDAQ:RCEL) reported Q2 net loss of $7.7M, nearly $3M better than Q1, with cash use down to $3.2M and cash of $11.1M at quarter end. The company raised its 2026 revenue outlook and said it is within Perceptive Advisors debt revenue covenants, including a $73M 2026 target. Q2 sales rose 18%.

yahoo.com7 min
AUG 13
$RCELMedAI 8/10

AVITA Medical (RCEL) Q2 2026 Earnings Call Transcript

AVITA Medical (RCEL) reported Q2 2026 revenue of $21.7M, up 18% year over year and 13% sequentially. RECELL revenue was $18.5M, Cohealyx $1.7M, and PermeaDerm $0.6M. Gross margin was 81.9%. Net loss was $7.7M ($0.25/share). Full-year 2026 guidance is $86M to $89M; cash flow breakeven targeted for Q4 2026.

fool.com7 min
AUG 8
$RCELHighAI 9/10

Avita Medical Shares Surge After Record Second-Quarter Performance

Avita Medical (NASDAQ:RCEL) shares rose about 21.7% in premarket after it reported record Q2 results. Revenue was $21.7M, up 18% YoY and about 8% above estimates. Adjusted loss per share narrowed to $0.25 vs $0.30 expected. Full-year 2026 revenue guidance raised to $86M-$89M and cash-flow breakeven targeted for Q4 2026. BTIG upgraded to Buy with a $7.00 target.

yahoo.com4 min
AUG 7
$RCELHighAI 9/10

Why is Avita Medical stock surging 20% today?

Avita Medical (RCEL) shares rose about 22% pre-open after the company reported Q2 revenue of $21.7M, up 18% YoY and about 8% above consensus, with adjusted loss per share of $0.25 vs $0.30 expected. The firm raised 2026 revenue guidance to $86M-$89M and reiterated cash-flow breakeven in Q4 2026. BTIG upgraded RCEL to Buy and set a $7 target.

investing.com4 min
AUG 6
$RCELHigh

AVITA Medical Reports Second Quarter Results

AVITA Medical, Inc. (RCEL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 AVITA Medical Reports Second Quarter Results, Raises 2026 Revenue Guidance, and Expects Fourth Quarter Cash Flow Breakeven VALENCIA, Calif., August 6, 2026 (GLOBE NEWSWIRE) — AVITA Medical ® , Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care comp

SEC EDGAR 8-K6 min